Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 127

Sort by

Sort Order Select

Journal Articles

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

Shalev Fried, Ivetta Danylesko, Ronit Marcus, Orit Itzhaki, Ronit Yerushalmi, Noga Shem-Tov, Inbal Sdayoor, Roni Shouval, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 6875.

https://doi.org/10.1182/blood-2023-178477

Published: 2023

Journal Articles

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6908.

https://doi.org/10.1182/blood-2023-187338

Published: 2023

Journal Articles

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Avichai Shimoni, Ronit Yerushalmi, Noga Shem-Tov, Ivetta Danylesko, Abraham Avigdor, Arnon Nagler

Blood (2023) 142 (Supplement 1): 3591.

https://doi.org/10.1182/blood-2023-184520

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Ron Ram, Ido Wolf, Odelia Amit, Ronit Yerushalmi, Yakir Moshe, Noga Shem-Tov, Gil Fridberg, Ivetta Danylesko, Irit Avivi Mazza, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3590.

https://doi.org/10.1182/blood-2023-182826

Published: 2023

Journal Articles

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Ivetta Danylesko, Avichai Shimoni, Abraham Avigdor, Meirav Kedmi, Noga Shem-Tov, Ronit Yerushalmi, Maya Sasson, Dan Dominissini, Borje S. Andersson, Arnon Nagler

Blood (2023) 142 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2023-178286

Published: 2023

Journal Articles

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Inbal Sdayoor, Roni Shouval, Shalev Fried, Ronit Marcus, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Orit Itzhaki, Elad Jacoby, Meirav Kedmi, Arnon Nagler, Avichai Shimoni, Michael J Segel, Abraham Avigdor

Blood (2023) 142 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2023-180115

Published: 2023

Journal Articles

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Ivetta Danylesko, Yana Davidov, Noga Shem-Tov, Ronit Yerushalmi, Ziv Ben-Ari, Arnon Nagler, Avichai Shimoni

Blood (2023) 142 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2023-179990

Published: 2023

Journal Articles

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

Katia Beider, Ilana Kalnitsky, Nira Varda-Bloom, Olga Ostrovsky, Avichai Shimoni, Hila Magen, Arnon Nagler

Blood (2023) 142 (Supplement 1): 875.

https://doi.org/10.1182/blood-2023-180516

Published: 2023

Journal Articles

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

Liron Miller, Mor Freed-Freundlich, Tamer Hellou, Avichai Shimoni, Abraham Avigdor, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 5717–5718.

https://doi.org/10.1182/blood-2022-156096

Published: 2022

Journal Articles

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Tamer Hellou, Omri Cohen, Abraham Avigdor, Avichai Shimoni, Mudi Misgav, Jonathan Canaani

Blood (2022) 140 (Supplement 1): 3229–3230.

https://doi.org/10.1182/blood-2022-156099

Published: 2022

Journal Articles

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 648–650.

https://doi.org/10.1182/blood-2022-162286

Published: 2022

Journal Articles

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Katia Beider, Noy Sharvit Boaron, Valeria Voevoda, Olga Ostrovsky, Ivetta Danylesko, Avichai Shimoni, Amnon Peled, Arnon Nagler

Blood (2022) 140 (Supplement 1): 5969–5970.

https://doi.org/10.1182/blood-2022-164646

Published: 2022

Journal Articles

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Meirav Kedmi, Elena Ribakovsky, Ohad Benjamini, Avichai Shimoni, Abraham Avigdor

Blood (2022) 140 (Supplement 1): 12071–12072.

https://doi.org/10.1182/blood-2022-158742

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2022) 140 (Supplement 1): 2306–2307.

https://doi.org/10.1182/blood-2022-164637

Published: 2022

Journal Articles

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

Gal Sharvit, Gabriel Heering, Maya Zlotnick, Arnon Nagler, Abraham Avigdor, Avichai Shimoni, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2021-145552

Published: 2021

Journal Articles

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Naama Keren Froim, Gabriel Heering, Gal Sharvit, Maya Zlotnick, Arnon Nagler, Avichai Shimoni, Abraham Avigdor, Jonathan Canaani

Blood (2021) 138 (Supplement 1): 3392.

https://doi.org/10.1182/blood-2021-145551

Published: 2021

Journal Articles

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

Evgenia Rosenberg, Valeria Voevoda, Hila Magen, Olga Ostrovsky, Avichai Shimoni, Amnon Peled, Arnon Nagler, Katia Beider

Blood (2021) 138 (Supplement 1): 1195.

https://doi.org/10.1182/blood-2021-149372

Published: 2021

Journal Articles

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Blood (2021) 138 (Supplement 1): 883.

https://doi.org/10.1182/blood-2021-147568

Published: 2021

Journal Articles

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Shalev Fried, Ivetta Danylesko, Ronit Yerushalmi, Noga Shem-Tov, Roni Shouval, Joshua A Fein, Zachary Cohen, Elad Jacoby, Michal Besser, Arnon Nagler, Avichai Shimoni, Abraham Avigdor

Blood (2021) 138 (Supplement 1): 910.

https://doi.org/10.1182/blood-2021-147148

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study

Oren Pasvolsky, Shai Shimony, Ron Ram, Avichai Shimoni, Liat Shargian-Alon, Batia Avni, Ofir Wolach, Tzippy Shochat, Ronit Yerushalmi, Odelia Amit, Pia Raanani, Moshe Yeshurun

Blood (2021) 138 (Supplement 1): 3962.

https://doi.org/10.1182/blood-2021-144772

Published: 2021

NARROW

High Response Rates Following Point-of-Care Anti-CD19 CAR T-Cell Therapy in Adults with Relapsed/Refractory Acute B Lymphoblastic Leukemia

The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Allogeneic Stem Cell Transplantation with Myeloablative Compared with Reduced- Intensity Conditioning for AML and Mds; 20 Years Later

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Active Primary Malignancy at HCT - a Bi-Institutional Retrospective Cohort Analysis

Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study

Pre-Treatment Pulmonary Assessment Have Limited Utility in B-Cell Lymphoma Patients Treated with Autologous Anti-CD19 CAR T-Cell Therapy

Prediction of Sinusoidal Obstructive Syndrome after Allogeneic Stem Cell Transplantation Using Liver Stiffness Measurement By Fibroscan

Mitochondrial Fitness and Immune Function of Natural Killer Cells Are Impaired By the Multiple Myeloma (MM) Tumor Cells: The Role of MM Microenvironment Interactions

Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients

The Occurrence of Thrombosis during Intensive Chemotherapy Treatment for Acute Myeloid Leukemia Patients Does Not Impact on Long-Term Survival

Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy

CXCR4 Promotes Bortezomib Resistance and Regulates Metabolic Reprogramming, Activating Both Glycolytic and Oxphos Pathways in Multiple Myeloma

Nivolumab Maintenance in First Complete Remission of Diffuse Large B-Cell Lymphoma

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Acute Myeloid Leukemia Patients Requiring Two Cycles of Intensive Induction for Attainment of Remission Experience Inferior Survival Compared with Patients Requiring a Single Course of Induction Chemotherapy

ELN 2017 Classification Significantly Impacts on the Risk of Early Death in Acute Myeloid Leukemia Patients Receiving Intensive Induction Chemotherapy

Venetoclax Reverses Metabolic Reprogramming Induced By S1P Modulator FTY720, Suppresses Oxidative Phosphorylation and Synergistically Targets Multiple Myeloma

Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study

Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission after 5-Azacitidine and Venetoclax: A Multicenter Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only